GSK terminates $700 million Alector partnership after recent trial setbacks

GSK has decided to end its collaboration with Alector, a biotech focused on neurodegenerative diseases. The agreement originally included a $700 million upfront payment.

The move follows two high-profile clinical trial failures that GSK experienced over the past year, prompting the company to reassess its immuno-neurology strategy.

By walking away, GSK will forgo further payments under the deal, while Alector will retain any data generated to date. The termination underscores the challenges of developing treatments for neurodegenerative conditions.